Dismissing critical reports on patient deaths, FDA says safety/effectiveness of Nuplazid holds up under review
Not long after Acadia’s Nuplazid hit the market, green lighted by the FDA despite its own in-house concerns about a possible link to patient deaths …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
